サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1293850

非アルコール性脂肪肝炎（NASH）治療薬市場- 成長、将来展望、競合分析、2023年～2031年

Nonalcoholic Steatohepatitis (NASH) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 120 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
非アルコール性脂肪肝炎（NASH）治療薬市場- 成長、将来展望、競合分析、2023年～2031年
出版日: 2023年05月06日
発行: Acute Market Reports
ページ情報: 英文 120 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非アルコール性脂肪肝炎（NASH）治療薬市場は、2031年までに38%の成長が見込まれます。非アルコール性脂肪肝炎（NASH）は、アルコール依存症ではない患者に発症する疾患で、主にアルコール性肝炎と診断上区別がつかないほどの肝障害を引き起こすことから、「脂肪肝」とも呼ばれます。NASHに罹患している患者さんに見られる主な危険因子は、肥満、耐糖能異常、脂質異常症です。この疾患の診断で直面する課題は、主に、特に肥満やメタボリックシンドロームにおけるインスリン抵抗性に関連する病因の理解が不十分であることに起因しています。市場の専門家によると、患者の多くは無症状で、NASHに関連する検査所見は主にアミノトランスフェラーゼ値の上昇です。しかし、NASHの診断においては、生検が重要な役割を果たします。米国肝臓財団によると、NASHは米国における肝移植の第3の原因であり、データベースによると、一般人口の12％以上がNASHを発症し、約2.7％がこの疾患により肝線維化が進行しています。NASHは、肥満治療、インスリン感受性改善剤、脂質低下剤、抗酸化剤、肝保護療法などで構成されています。NASHの治療において、減量は成人において広く研究されており、生化学的な結果だけでなく、組織学的な改善も示されています。

Cleveland Clinicによると、食事の炭水化物、特に食事の果糖を減らすことが最も有効であり、過体重の患者の脂質プロファイルを改善することが判明しています。セロトニン再取り込み阻害剤のシブトラミンや、脂肪の吸収を抑えるオルリスタットなど、いくつかの薬剤が研究されています。これらはいずれも、肝酵素値や脂肪肝の超音波診断の兆候を改善することが示されています。カンナビノイド-1-拮抗薬であるリモナバントのメタアナリシスでは、有害事象が増加することが示され、現在NAFLDに対して推奨できないです。インスリン感受性増強剤では、ペルオキシソーム増殖剤活性化受容体γ（PPARg）作動薬（チオグリタゾン）が脂肪肝の代用マーカーとして作用し、肝臓や筋肉から増殖脂肪細胞へのトリグリセリドの再分配を促進し、インスリン抵抗性を改善することが予測されています。最近発表された「チリ消化器学会」と「チリ肝臓学会」の専門家による総説によると、ピオグリタゾンとビタミンEの併用は、生検で証明されたNASH患者に対する薬理学的選択肢であることは証明されているが、その長期安全性と有効性に関する証拠は不足しています。さらに、米国肝臓病学会のガイドラインでは、ピオグリタゾンはNASHの治療薬として可能性があるとされています。

NASH治療薬の最大市場は北米で、次いで欧州であることが確認されました。北米では、肥満の増加、糖尿病の発症率の増加が、NASH治療薬市場を支える主要な要因となっています。Cleveland Clinicによると、米国における体重超過者の有病率は65％以上に達し、現在、米国の成人人口の30％以上に肥満が見られます。男性、高齢者（40-70歳）、メタボリックシンドローム（特に糖尿病と腹部肥満）の構成要素を持っている人ほど、その有病率は高くなります。小児肥満と非アルコール性脂肪性肝疾患（NAFLD）の有病率は同程度です。NAFLDはすべての民族で観察され、白人やアフリカ系アメリカ人に比べ、ヒスパニック系で最も高い有病率を示しているアジア太平洋地域が予測期間中に最も速いCAGRで成長すると予測されている

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ-二次調査
    • フェーズⅡ-一次調査
    • フェーズⅢ-有識者別レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 非アルコール性脂肪肝炎（NASH）治療薬市場：競合分析

  • 主要ベンダーの市場での位置付け
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs 2031

第4章 非アルコール性脂肪肝炎（NASH）治療薬市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の非アルコール性脂肪肝炎（NASH）治療薬市場金額
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 非アルコール性脂肪肝炎（NASH）治療薬市場：薬剤の種類別

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • ビタミンEとピオグリタゾン
    • オベチコール酸（OCA）
    • ラニフィブラノール
    • セマグルチド
    • レスメティロム
    • アラムチョル
    • セニクリビロック
    • その他

第6章 非アルコール性脂肪肝炎（NASH）治療薬市場：最終用途別

  • 市場概要
  • 成長・収益分析：2022 vs 2031
  • 市場セグメンテーション
    • 病院薬局
    • 小売店および専門薬局
    • その他

第7章 北米の非アルコール性脂肪肝炎（NASH）治療薬市場

  • 市場概要
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：薬剤の種類別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：最終用途別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：地域別
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国と欧州連合の非アルコール性脂肪肝炎（NASH）治療薬市場

  • 市場概要
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：薬剤の種類別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：最終用途別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：地域別
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋の非アルコール性脂肪肝炎（NASH）治療薬市場

  • 市場概要
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：薬剤の種類別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：最終用途別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：地域別
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカの非アルコール性脂肪肝炎（NASH）治療薬市場

  • 市場概要
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：薬剤の種類別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：最終用途別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：地域別
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東・アフリカの非アルコール性脂肪肝炎（NASH）治療薬市場

  • 市場概要
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：薬剤の種類別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：最終用途別
  • 非アルコール性脂肪肝炎（NASH）治療薬市場：地域別
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • Intercept Pharmaceuticals
  • Galmed Pharmaceuticals
  • Inventiva Pharma
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.
図表

List of Tables

  • TABLE 1 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 2 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 3 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 4 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 5 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 6 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 7 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 8 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 13 UK Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 14 UK Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 15 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 16 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 17 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 18 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 19 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 20 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 21 France Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 22 France Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 25 Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 26 Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 27 China Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 28 China Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 29 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 30 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 31 India Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 32 India Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 33 Australia Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 34 Australia Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 35 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 36 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 37 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 38 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 39 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 40 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 41 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 42 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 47 GCC Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 48 GCC Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 49 Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 50 Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By Drug Type, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market By End-use, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Quality Assurance
  • FIG. 5 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022
  • FIG. 6 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022
  • FIG. 7 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2022
  • FIG. 9 Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Players, 2022
  • FIG. 10 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 11 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022 Vs 2031, %
  • FIG. 12 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022 Vs 2031, %
  • FIG. 13 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 20 France Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 22 China Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 24 India Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market (US$ Million), 2021 - 2031
目次
Product Code: 137073-05-23

Nonalcoholic Steatohepatitis (NASH) Treatment Market is Expected to Grow at 38% by 2031. Nonalcoholic steatohepatitis (NASH) is also known as 'fatty liver' a disorder that develops in patients who are not alcoholic; mainly causes liver damage that is diagnostically indistinguishable from alcoholic hepatitis. The key risk factors observed in patients suffering from NASH are obesity, glucose intolerance, and dyslipidemia. The challenges that are faced in the diagnosis of the disease are mainly due to poor understanding of pathogenesis linked to insulin resistance especially in obesity or metabolic syndrome. Market experts suggest that most of the patients are asymptomatic and laboratory findings related with NASH mainly include elevations in aminotransferase levels. However, in diagnosis of NASH biopsy pays key role in diagnosis. According to American Liver Foundation, NASH is the third leading cause of liver transplant in the U.S.; database suggests more than 12% of the general population has NASH and approximately 2.7% have advanced liver fibrosis due to the disease. NASH comprises treatment of obesity, insulin-sensitizing agents, lipid-lowering agents, antioxidants, and hepatoprotective therapy. In NASH treatment weight reduction has been widely studied in adults and has shown improvement not only the biochemical results but also the histology.

According to Cleveland Clinic, the reduction of dietary carbohydrates, in particular dietary fructose, is the most beneficial and has been found to improve the lipid profile in overweight patients. Several drugs have been studied, including sibutramine, a serotonin reuptake inhibitor, and orlistat, which reduce fat absorption. Both of these have been shown to improve liver enzyme levels and sonographic signs of fatty liver. A meta-analysis of rimonabant, a cannabinoid-1-antagonist, showed that it is associated with increased adverse events and currently it cannot be recommended for NAFLD. In case of insulin-sensitizing agents, peroxisome proliferator-activated receptor gamma (PPARg) agonists (thioglitazones) have projected improvement in insulin resistance, by acting as surrogate marker of fatty liver, and promoting redistribution of triglycerides from the liver and muscle into proliferating adipocytes. According to a recently published review article that was conducted by an expert panel from the "Chilean Gastroenterological Society" and the "Chilean Hepatology Association" suggested that pioglitazone along with vitamin E is a proven pharmacological choice for patients with biopsy-proven NASH, however evidence on its long-term safety and efficacy is lacking. Moreover, the guidelines of the American Association for the Study of Liver Diseases indicate pioglitazone as a possible therapeutic drug for the treatment of NASH.

North America was observed as the largest market for NASH treatment followed by Europe. In North America, the rising prevalence of obesity, and the increasing incidence of diabetes are the key factors assisting the NASH treatment market. According to Cleveland Clinic, The prevalence of overweight persons in the US has risen to more than 65%, and obesity is now present in more than 30% of the adult US population. The prevalence is increased in men, older individuals (those aged 40-70 years), and those with components of the metabolic syndrome especially diabetes and abdominal obesity. The prevalence of childhood obesity and non-alcoholic fatty liver disease (NAFLD) is at similar levels. NAFLD has been observed in all ethnic groups with the highest prevalence seen in Hispanics compared with Caucasians and African Americans Asia Pacific was anticipated to grow at the fastest CAGR during the forecast period.

Key Players Identified for Non-Alcoholic Steatohepatitis (NASH) Treatment Market Include but are Not Limited to:

  • Intercept Pharmaceuticals
  • Galmed Pharmaceuticals
  • Inventiva Pharma
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals
  • NGM Biopharmaceuticals Inc.
  • Novo Nordisk A/S
  • Bristol Myers Squibb
  • Gilead Sciences Inc.

Historical & Forecast Period

This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review.A key data point that enables the estimation of Nonalcoholic Steatohepatitis (NASH) Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Nonalcoholic Steatohepatitis (NASH) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approaches for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Segmentation

Drug Type

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Others

End-use

  • Hospital Pharmacies
  • Retail & Specialty Pharmacies
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • Which is the largest regional market for Nonalcoholic Steatohepatitis (NASH) Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Nonalcoholic Steatohepatitis (NASH) Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Nonalcoholic Steatohepatitis (NASH) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
  • 2.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022 (US$ Million)
  • 2.3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-use, 2022 (US$ Million)
  • 2.4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
  • 3.2. Strategies Adopted by Nonalcoholic Steatohepatitis (NASH) Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Nonalcoholic Steatohepatitis (NASH) Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Vitamin E and Pioglitazone
    • 5.3.2. Obeticholic Acid (OCA)
    • 5.3.3. Lanifibranor
    • 5.3.4. Semaglutide
    • 5.3.5. Resmetirom
    • 5.3.6. Aramchol
    • 5.3.7. Cenicriviroc
    • 5.3.8. Others

6. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Specialty Pharmacies
    • 6.3.3. Others

7. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 7.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 7.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 7.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

8. UK and European Union Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 8.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 8.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 8.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

9. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 9.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 9.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.4.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.5.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 9.4.1.6.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

10. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 10.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 10.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 10.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

11. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
  • 11.3. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
  • 11.4.Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.1.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.2.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By Drug Type, 2021-2031, USD (Million)
        • 11.4.1.3.1. Nonalcoholic Steatohepatitis (NASH) Treatment Market: By End-use, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Intercept Pharmaceuticals
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Galmed Pharmaceuticals
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Inventiva Pharma
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. AbbVie Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Galectin Therapeutics Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Madrigal Pharmaceuticals
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. NGM Biopharmaceuticals Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. Novo Nordisk A/S
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Bristol Myers Squibb
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Gilead Sciences Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives